In 2023, Canada led the sales of global modulators of the genital system and sex hormones with significant sales of 581.9 million USD despite a slight decline of 1.85%. South Korea showed a positive trend with a 3.94% increase in sales valued at 235.7 million USD, while New Zealand experienced the highest growth rate at 6.76% albeit from a smaller base of 10.4 million USD. Conversely, markets like Slovenia and Hungary exhibited notable declines, with Slovenia experiencing the steepest drop at 7.57%. Among European countries, Italy and Greece saw significant reductions in sales, with a decrease of 5.05% and 4.03%, respectively.
Looking ahead, future trends in 2024 for the modulators of the genital system and sex hormones will likely be influenced by increasing demand for personalized medicine and rising awareness about hormonal therapies. Markets like South Korea and New Zealand are expected to continue their growth trends, while European markets may face challenges due to regulatory changes and competitive pressures. Staying adaptable to these evolving trends will be key for stakeholders in the industry.
Top countries in Modulators of the Genital System and Sex Hormones Sales by Country
| # | 10 Countries | Million US Dollars | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Canada | 581.9 | 2023 | -0.6% | -1.85% | View data |
| 2 | 2 South Korea | 235.7 | 2023 | +3.15% | +3.94% | View data |
| 3 | 3 Chile | 212.9 | 2023 | +14.4% | +0.89% | View data |
| 4 | 4 Belgium | 117.1 | 2023 | +2.09% | -1.42% | View data |
| 5 | 5 Italy | 102.2 | 2023 | -7.59% | -5.05% | View data |
| 6 | 6 Sweden | 100.4 | 2023 | +0.5% | -1.06% | View data |
| 7 | 7 Denmark | 73 | 2023 | -0.82% | -0.88% | View data |
| 8 | 8 Portugal | 65.4 | 2023 | -0.91% | -1.85% | View data |
| 9 | 9 Greece | 39.8 | 2023 | -0.5% | -4.03% | View data |
| 10 | 10 Slovakia | 21.6 | 2023 | +0.47% | 0% | View data |
